@ShapeTx

Shaping the future of Gene Therapy

 Seattle
shapetx.com
Joined May 2019
  • Tweets105
  • Following32
  • Followers335
40Media
Ron Hause, SVP, Head of AI, describes Shape's approach, which is meant to be a one time treatment without introducing any inheritable DNA edits. biotechtv.com/post/shape-the…

Seattle based Shape Therapeutics is aiming to reprogram cells by delivering guide RNAs via AAV - it...

Ron Hause, SVP, Head of AI, describes Shape's approach, which is meant to be a one time treatment without introducing any inheritable DNA edits.Seattle based Shape Therapeutics is aiming deliver...

biotechtv.com
273
How do you turn AI conversations into real progress? Next week at Benchtalk 2024, Generate’s @tharindi_h, PhD, joins @WillWeiss of @EliLillyandCo and @RonHause from @ShapeTx Inc. to discuss R&D’s toughest challenges. Don’t miss out—details here: benchtalk.benchling.com/bost…
1
1
648
We are pleased to welcome @DavidEpsteinRX and Todd Simpson to our board of directors. Their collective experience and expertise will be invaluable as we continue to advance our transformative science and drive growth. globenewswire.com/news-relea…

Shape Therapeutics Appoints Healthcare Industry Leaders David Epstein and Todd Simpson to its Board...

Shape Therapeutics Appoints Healthcare Industry Leaders David Epstein and Todd Simpson to its Board of Directors...

globenewswire.com
1
186
Lessons from Shape Therapeutics: How to harness AI for R&D success benchling.com/blog/lessons-f…

Lessons from Shape Therapeutics: How to harness AI for R&D success | Benchling

Read learnings and tactics from Ron Hause, SVP and Head of AI at Shape Therapeutics, where generative AI is critical to their process of developing programmable RNA therapeutics.

benchling.com
205
Very exciting news from the recent ASGCT meeting! globenewswire.com/en/news-re…

Shape Therapeutics RNAfix® Editing Platform Achieves >90% Editing in Mouse and Non-Human Primate...

RNAfix achieves up to 92% editing in the non-human primate brain after AAV-based gRNA delivery RNAfix achieves >95% editing throughout the mouse brain...

globenewswire.com
2
160
ShapeTX is once again taking over Union Square for #JPM2024! Look out for our kiosk ads throughout the area and visit ShapeTX.com to learn more about our work in engineering programmable medicines!
1
4
327
Heading to #JPM2024 next week? Meet with us onsite to learn more about our work creating programmable medicines with AI and RNA! Reach out via our contact form to set up a meeting: bit.ly/47mT99A
1
219
Calling all JPM Healthcare Conference attendees - join our VP of Process and Product Development, Ken Prentice as he moderates a panel on next-generation gene therapy for @GenScript's Biotech Global Forum on Jan 10 at 3:20 PM! Tickets available here: bit.ly/3S6yu4b
1
2
225
Our latest news update was an expansion of our partnership with @Roche. In December, @Roche added an additional target by utilizing our AI-powered RNAfix™ platform. A great way to close out 2023! Read about this and other ShapeTX news via @FierceBiotech bit.ly/3R1l4pw

Phenomic AI inks second deal in two days, Shape stretches Roche collab

Phenomic AI has largely lived off the grid since launching more than three years ago, but it’s now sprinting onto the scene with a second collaboration in as many days, this time with Astellas.&nbs |...

fiercebiotech.com
1
186
We’ve enjoyed many great successes in 2023 thanks to our partners. In fall we announced our collaboration w/ Otsuka to apply our generative AI and AAVid™ capsid discovery platform w/ Otsuka’s expertise in ocular diseases to create novel treatment options bit.ly/3ZjG1je

Otsuka's eye disease strategy takes Shape with $1.5B biobucks deal

Barely a week after Otsuka Pharmaceutical made moves into the psychedelics space, the Japanese drugmaker has clinched a

fiercebiotech.com
166
Looking back on our proudest moments of 2023, our SVP and Head of AI Ron Hause's byline in @FastCompany is on our list! Read about how biotechs like ShapeTX are expanding the possibilities of generative AI for the next generation of drug development here: bit.ly/42XaFPC

POV: How generative AI could help to cure 'untreatable' diseases

In the long term, generative AI will help make drugs both more effective and more accessible.

fastcompany.com
123
As this year comes to a close, we're looking back on some of our proudest moments from 2023. In May, our CSO David Huss was named one of @endpts 20 under 40 in Biopharma. We're proud of David's ShapeTX accomplishments while also running 100+ mile races! bit.ly/48rrDbM

The 20(+2) under 40: Your guide to the next generation of biotech leaders

This year's list of 20 biotech leaders under the age of 40 includes a huge range of ambitions. Some of our honorees are planning to create the next big drug ...

endpoints.news
98
Our SVP and Head of AI Ron Hause leads a team using #generativeAI to develop programmable RNA medicines for disease treatment. What does that mean in practice? Check out Ron's Coworking feature in @etechbrew to learn more bit.ly/3uDWCmD
1
125
On the anniversary of ChatGPT's launch, @FastCompany asked asked AI leaders including our SVP and Head of AI Ron Hause how #generativeAI is changing drug development. Read their insights here: bit.ly/3RoUA2s

What year 2 of the generative AI craze will look like, according to 41 experts

To mark ChatGPT's anniversary, we asked 41 AI experts a simple question: How will generative AI tools like ChatGPT and Midjourney be applied over the next year to best help businesses function more...

fastcompany.com
1
2
145
ICYMI - we've expanded our partnership with @Roche to add an additional target by utilizing our AI-powered RNAfix™ platform. Read the latest on this deal and our Otsuka deal from earlier this year via @FierceBiotech: bit.ly/3R1l4pw

Phenomic AI inks second deal in two days, Shape stretches Roche collab

Phenomic AI has largely lived off the grid since launching more than three years ago, but it’s now sprinting onto the scene with a second collaboration in as many days, this time with Astellas.&nbs |...

fiercebiotech.com
1
130
We've expanded our work with @Roche to add a new target to our existing collaboration. For this partnership, we're conducting preclinical research to identify and deliver development candidates discovered by our AI-powered RNAfix™ platform: bit.ly/46DGwql
1
3
184
2023 was a meaningful year for the cell and gene therapeutics industry, and we were proud to announce our partnership with Otsuka. We look forward to continued industry growth in 2024: bit.ly/3ujAX2K

Pharma spends big to access key cell and gene therapy assets

Biopharma Dealmakers - High-value cell therapy deals are driving investment in the cell and gene therapy field, but new approaches such as gene editing are also beginning to contribute.

nature.com
125
ShapeTX CTO Adrian Briggs has always been drawn to solving seemingly insurmountable scientific problems. Learn how Adrian's scientific journey has brought him to leading a team that is creating disruptive end-to-end gene therapies in his employee spotlight bit.ly/3ukpeAV

Spotlight Video: Dr. Adrian Briggs’ Next Scientific Puzzle - ShapeTX

For ShapeTX Chief Technology Officer Adrian Briggs, scientific discovery has been a fascination since childhood. He grew up around many family members who made science their lives’ work, including an...

shapetx.com
129
There's been a big milestone in the therapeutics community - we're thrilled to see the UK approval of the first CRISPR medicine, and we look forward to the day the first RNA editing therapy is approved for treating genetic diseases! bit.ly/40FterM
1
166
ShapeTX scientist Lina Bagepalli designs guide RNAs for efficient and specific RNA editing to correct genetic mutations that cause disease. See how Lina's scientific work mirrors her artistic process, finding the balance between control and experimentation bit.ly/3MfphnL
1
181
Load more